Found: 6
Select item for more details and to access through your institution.
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 10, p. 1576, doi. 10.1177/13524585221079731
- By:
- Publication type:
- Article
(DXT02) Early Effect of Ofatumumab on B-Cell Counts and Magnetic Resonance Imaging Activity in Relapsing Multiple Sclerosis Patients: Results from the APLIOS Study.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 16
- By:
- Publication type:
- Article
Response to the letter to the editor regarding our article 'statistical methodology for highly variable compounds: A novel design approach for the ofatumumab phase 2 bioequivalence study' https://doi.org/10.1002/pst.2233.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1368, doi. 10.1002/pst.2254
- By:
- Publication type:
- Article
Statistical methodology for highly variable compounds: A novel design approach for the ofatumumab Phase 2 bioequivalence study.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1357, doi. 10.1002/pst.2233
- By:
- Publication type:
- Article
Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial.
- Published in:
- Neurology & Therapy, 2023, v. 12, n. 1, p. 303, doi. 10.1007/s40120-022-00427-8
- By:
- Publication type:
- Article
Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis.
- Published in:
- CNS Drugs, 2022, v. 36, n. 3, p. 283, doi. 10.1007/s40263-021-00895-w
- By:
- Publication type:
- Article